BridgeBio team clears a key hurdle with their proof-of-concept data for a rare genetic disease. And they can thank the NIH for a quick success
BridgeBio’s Calcilytix team has several good reasons to offer some special thanks to the NIH today.
Mike Collins, an NIH researcher and division chief who specializes in bone and mineral metabolism, suggested the idea that the right calcium sensing receptor (CaSR) antagonist could provide a direct way to treat a rare disease called ADH1, a genetic ailment that triggers a dangerous imbalance in calcium in a small patient population.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.